Evidence map›Paper›PMID 39113010›Full record

ArticleBMC women's health2024

Immune-related gene signature improves prognosis prediction in patients with breast cancer and associates it with tumor immunity and inflammatory response.

Haiping Zhang, Lu Sun, Jingjing Liu, Jing Wang, Lingchao Meng, Yuan Gao, Jingwu Li, Qi Zhou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC women's health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Haiping ZhangDepartment of Breast Surgery, Tangshan People's Hospital, Tangshan, Hebei, 063001, China.
Lu SunDepartment of Chemoradiotherapy, Tangshan People's Hospital, Tangshan, Hebei, 063001, China.
Jingjing LiuDepartment of Chemoradiotherapy, Tangshan People's Hospital, Tangshan, Hebei, 063001, China.
Jing WangDepartment of Breast Surgery, Tangshan People's Hospital, Tangshan, Hebei, 063001, China.
Lingchao MengDepartment of Pathology, Tangshan People's Hospital, Tangshan, Hebei, 063001, China.
Yuan GaoCollege of Life Sciences, North China University of Science and Technology, Tangshan, Hebei Province, China.
Jingwu Li *Department of Breast Center, Tangshan People's Hospital, Tangshan, Hebei, 063001, China. tslijingwu@163.com.
Qi Zhou *Department of Breast Surgery, Tangshan People's Hospital, Tangshan, Hebei, 063001, China. qzhou83@cmu.edu.cn.

Funding

the Research Fund Project of Hebei Provincial Health Commission 20231811
6 · The paper itself

Abstract

backgroundThe prognostic potential of immune-related genes, particularly immune checkpoint inhibitors (ICIs) and long non-coding RNAs (lncRNAs), is gaining attention for evaluating the prognosis of breast cancer patients.

methodsWe analyzed 23 datasets to identify 15 ICI-related mRNAs and 5 immune-related lncRNAs, creating a robust immune score (IS). This score was used to classify patients into high and low IS groups and assess their survival outcomes.

resultsPatients with high IS showed significantly poorer overall survival (OS) and progression-free survival (PFS) compared to those with low IS. Multivariate Cox regression analysis confirmed IS as an independent prognostic factor. Additionally, high IS was associated with higher mutation loads and neoantigen profiles, while low IS correlated with enhanced immune cell infiltration.

conclusionsThe immune score developed from ICI-related mRNAs and lncRNAs effectively predicts the prognosis of breast cancer patients and highlights the differential immune and inflammatory responses between patients with varying levels of immune score. This underscores the relevance of IS in guiding therapeutic decisions and tailoring patient management strategies in clinical settings.

Indexed as

Breast NeoplasmsRNA, Long NoncodingBiomarkers, TumorFemaleHumansImmune Checkpoint InhibitorsInflammationMiddle AgedPrognosisRNA, MessengerTranscriptomeBiomarkers, TumorImmune Checkpoint InhibitorsRNA, Long NoncodingRNA, MessengerBreast cancerImmune cellsImmune checkpoint inhibitorsImmune prognostic signaturelncRNA

Identifiers

PMID39113010
PMCPMC11304607

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.